Ali Erginay · enciclopedia

Publicaciones › Enfermedades vasculares, genéticas e inflamatorias de la retina

Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2

Análisis combinado de datos anatómicos y de función visual de revakinagene taroretcel-lwey en participantes con telangiectasia macular tipo 2

Año2026
FuenteOphthalmology Retina
Tipoarticle
Autores (49)Roger A. Goldberg, Debora C. Manning, Joanna Yankey, W. Lloyd Clark, Muna I. Bitar, Emily Y. Chew, Martin Friedlander, Arshad M. Khanani, Glenn J. Jaffe, Eleonora Maries Lad, Thomas A. Aaberg, Ian Jeffery Constable, Chandra Balaratnasingam, Fred Kuanfu Chen, Alain Gaudric, Bénédicte Dupas, Ali Erginay, Corinne Guérin, Aude Jacob, Valérie Krivosic, Valérie Mané, Julie Smati, Catherine A. Egan, Odysseas Georgiadis, James W. Bainbridge, Edward Bloch, Lyndon da Cruz, Simona Degli Esposti, Blanca Flores, Tjebo F. C. Heeren, Yanling Ouyang, Filipa Gomes Rodrigues, Taha Soomro, Sandra Vermeirsch, Peter Charbel Issa, Robert Edward MacLaren, Steven D. Schwartz, Jean‐Pierre Hubschman, Greg Budoff, Ismaël Chehaibou, Alexander Dillon, A Francone, Wei Gui, Samuel David Hobbs, Hamid Hosseini, Kirk Hou, Jason Huang, Nicholas Iafe, Nikisha Kothari
Posición de Erginay17 de 49
Citas0 (OpenAlex)
EnlacesDOI 10.1016/j.oret.2026.07.005 · PubMed 42476337 · OpenAlex · Texto completo en acceso abierto
LíneasEnfermedades vasculares, genéticas e inflamatorias de la retina

En pocas palabras

Se estudió el efecto de revakinagene taroretcel-lwey en pacientes con telangiectasia macular tipo 2 mediante tres ensayos clínicos controlados. Los resultados mostraron que este tratamiento reduce la progresión de la enfermedad y preserva la función visual, disminuyendo la pérdida de zona elipsoide y la velocidad de lectura, así como la sensibilidad retiniana. Esto sugiere un beneficio potencial para los pacientes con esta condición.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

PURPOSE: To assess anatomic and visual function data from 3 randomized, sham-controlled clinical trials of revakinagene taroretcel-lwey in participants with macular telangiectasia type 2 (MacTel). DESIGN: This study pooled data from 1 phase II (NTMT-02) clinical trial and 2 identically designed phase III (NTMT-03-A and NTMT-03-B) clinical trials of revakinagene taroretcel-lwey in MacTel. PARTICIPANTS: In total, 67 participants (99 eyes) from NTMT-02, 115 participants (115 eyes) from NTMT-03-A, and 113 participants (113 eyes) from NTMT-03-B were included in the study. The pooled population included 327 eyes from 295 participants (165 participants who received revakinagene taroretcel-lwey and 162 who underwent sham surgical procedure). METHODS: Assessments were conducted on data from the individual trials as well as on a single pooled population from all 3 trials. MAIN OUTCOME MEASURES: The rate of ellipsoid zone (EZ) area loss over 24 months and changes from baseline in monocular reading speed loss, aggregate retinal sensitivity loss measured by microperimetry, and best-corrected visual acuity (BCVA) were assessed. RESULTS: /24 months; 95% CI, 0.154-0.217) (nominal P = 0.003). A 68.2% reduction in monocular reading speed loss at 24 months from baseline was observed with revakinagene taroretcel-lwey (-4.65 words per minute [WPM]; 95% CI, -9.58 to -0.27) versus sham (-14.60 WPM; 95% CI, -20.41 to -8.79) (nominal P = 0.01). Across the 3 trials, a 36.6% reduction in aggregate retinal sensitivity loss was reported over 24 months with revakinagene taroretcel-lwey (28.47 dB; 95% CI, 6.62-50.31) compared with sham (44.85 dB; 95% CI, 36.99-52.72) (nominal P < 0.001). Both treatment groups experienced minimal changes in BCVA over 24 months. CONCLUSIONS: In this pooled analysis, revakinagene taroretcel-lwey reduced the rate of MacTel disease progression and preserved visual function over 24 months, as shown by reductions in the rate of EZ area loss, reading speed loss, and aggregate retinal sensitivity loss. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.